A Phase 1/2 interventional study of LTX-002 and Placebo (aCSF) in Amyotrophic Lateral Sclerosis, sponsored by Leal Therapeutics, Inc. Recruiting at 5 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-18.
Sponsored by Leal Therapeutics, Inc · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 89 studies in Amyotrophic Lateral Sclerosis with a site in Italy — 27 open to participants now, 36 under way, 7 of them phase 3. Amyotrophic Lateral Sclerosis · Italy.
Among the 89 studies in Amyotrophic Lateral Sclerosis with a site in Italy, this one is the 48th largest by planned enrollment of the 69 interventional ones that give a count, is one of 7 that started in 2026, is one of 3 in phase 1/2, reaches primary completion later than 33 of the 35 other live ones, and was the 86th registered.
981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →27 of the 89 studies in Amyotrophic Lateral Sclerosis with a site in Italy are open now. Recruiting first, the newest first:
Prilenia · Sites in Italy, United States, Belgium and 10 more countries
Ages 18–80
Istituto Auxologico Italiano · Sites in Italy
Ages 18+
Zydus Therapeutics Inc. · Sites in Italy, United States, Australia and 9 more countries
Ages 18+
University of Trieste · Sites in Italy
Ages 18+
Istituti Clinici Scientifici Maugeri SpA · Sites in Italy
Ages 18–80
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
89 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 26 · Phase 3 24 · Phase 4 2
First in 2003; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 56 is above the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 87 across the 69 interventional studies, 200 across the 20 observational. Of the 46 that completed or were terminated, 23 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 89 have an industry lead sponsor. The 10 most frequent:
Leal Therapeutics, Inc is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Leal Therapeutics, Inc has 1 study filed under Amyotrophic Lateral Sclerosis — fewer than ten, so there is no comparison to draw.
11 of the studies in Amyotrophic Lateral Sclerosis with a site in Italy that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06126315Phase 3Mario Negri Institute for Pharmacological ResearchTrial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALS | 2027-04 |
| NCT04856982Phase 3BiogenStudy to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms | 2027-08-07 |
| NCT06881979Istituti Clinici Scientifici Maugeri SpAHigh-Tech Rehabilitation Pathway for Chronic Adult Neuromuscular Diseases - Fit4MedRob-Chronic MND Project | 2026-11 |
| NCT07616050Marta MondelliniEvaluation of the Impact of Virtual Park on Training Motivation in Adult Patients | 2026-12 |
| NCT06318585Istituto Auxologico ItalianoCreation of a Clinical Database for the Study of Phenotypic Variability in Motor Neuron Diseases | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 89 studies in Amyotrophic Lateral Sclerosis with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will examine what happens when patients with amyotrophic lateral sclerosis (ALS) are given an investigational medication (study drug) known as LTX-002. Specifically, the researchers will be looking at safety, tolerability (if someone has any side effects from the drug), pharmacokinetics (what the body does to the study drug) and pharmacodynamics (what the study drug does to the body). The study will also investigate the effect of the drug on indicators of the severity of ALS, such as markers in blood and in the cerebrospinal fluid (the fluid that surrounds the brain and spinal cord, CSF) and on measures of the participant's ability to move, speak, and breathe.
Eligible participants will be asked to visit the study site 9 times and stay overnight once. In addition, there will be telephone or video calls with the study staff on 8 separate occasions. Procedures will include:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LTX-002 is an antisense oligonucleotide (ASO) targeting SPTLC1 messenger RNA (mRNA). Several dose levels will be tested.
Drug: LTX-002
Sterile aCSF solution formulation intended for intrathecal administration.
Other: Placebo (aCSF)
LTX-002 is an antisense oligonucleotide (ASO) targeting SPTLC1 messenger RNA (mRNA). Several dose levels will be tested.
Sterile aCSF solution formulation intended for intrathecal administration.
Safety and Tolerability (Adverse Events)
Incidence and severity of adverse events (AEs), treatment-emergent adverse events (TEAEs) and serious adverse events
Time frame: Screening to Day 169
Safety and Tolerability (Clinical Laboratory Tests)
Clinical laboratory tests including serum chemistry and hematology; urinalysis
Time frame: Screening to Day 169
Safety and Tolerability (Vital Signs)
Vital signs will be collected, including blood pressure (mm Hg), heart rate (beats per minute), respiratory rate (breaths per minute), body temperature (°C or °F), total body weight (kilograms), and height (centimeters). Body Mass Index (BMI) will be calculated using the values of total body weight and height, with the formula BMI = weight in kg/(height in cm)\^2.
Time frame: Screening to Day 169
Safety and Tolerability (Physical and Neurological exams)
Physical and neurological exams will be performed periodically to ensure participant safety. Height (centimeters or inches), weight (kilograms or pounds) and body mass index (BMI; kilograms/meters\^2) will be measured.
Time frame: Screening to Day 169
Safety and Tolerability (ECGs - heart rate)
Cardiovascular safety will be monitored by performing electrocardiogram (ECG) assessments, including heart rate
Time frame: Screening to Day 169
Safety and Tolerability (ECGs - QRS)
Cardiovascular safety will be monitored by performing electrocardiogram (ECG) assessments, including the QRS complex (normally 70-100 ms)
Time frame: Time Frame: Screening to Day 169
Safety and Tolerability (ECGs - QT)
Description: Cardiovascular safety will be monitored by performing electrocardiogram (ECG) assessments, including the QT interval measure
Time frame: Screening to Day 169
Safety and Tolerability (ECGs - QTc)
Cardiovascular safety will be monitored by performing electrocardiogram (ECG) assessments, including QTc (heart rate-corrected QT interval)
Time frame: Screening to Day 169
Safety and Tolerability (ECGs - PR intervals)
Cardiovascular safety will be monitored by performing electrocardiogram (ECG) assessments, including PR intervals (normally 120-200 ms)
Time frame: Screening to Day 169
Pharmacokinetics of LTX-002 (CSF and plasma levels)
The amount of LTX-002 in the cerebrospinal fluid (CSF) and plasma will be measured.
Time frame: Day 1 to Day 169
Pharmacokinetics of LTX-002 (Cmax)
The maximum observed plasma concentration (Cmax) of LTX-002 will be calculated.
Time frame: Day 1 to Day 169
Pharmacokinetics of LTX-002 (Tmax)
The time to maximum observed plasma concentration (Tmax) of LTX-002 will be calculated.
Time frame: Day 1 through Day 169
Pharmacokinetics of LTX-002 (AUC0-∞)
The area under the plasma-time concentration curve from time 0 extrapolated to infinity (AUC0-∞) of LTX-002 will be calculated.
Time frame: Day 1 to Day 169
Pharmacokinetics of LTX-002 (AUC0-t)
The area under the plasma concentration-time curve from time 0 to the last measurable concentration (AUC0-t) of LTX-002 will be calculated.
Time frame: Day 1 to Day 169
Pharmacokinetics of LTX-002 (Tlag)
The delay between the time of dosing and the time of appearance of the first measurable concentration (Tlag) of LTX-002 in plasma will be calculated.
Time frame: Day 1 to Day 169
Pharmacokinetics of LTX-002 (Vd/F)
The apparent volume of distribution (Vd/F) of LTX-002 in plasma, if applicable, will be calculated.
Time frame: Day 1 to Day 169
Pharmacokinetics of LTX-002 (λz)
The apparent terminal elimination rate constant (λz) of LTX-002 in plasma, if applicable, will be calculated.
Time frame: Day 1 to Day 169
Pharmacokinetics of LTX-002 (T1/2)
The half-life (T1/2) of LTX-002 in plasma, if applicable, will be calculated.
Time frame: Day 1 to Day 169
Pharmacokinetics of LTX-002 (CL/F)
The apparent clearance (CL/F) of LTX-002 in plasma, if applicable, will be calculated.
Time frame: Day 1 to Day 169
Incidence of anti-LTX-002 antibodies in plasma
Number of participants with detectable anti-LTX-002 antibodies in plasma, as measured by a validated immunoassay. Antibody status and titers will be summarized descriptively by treatment group (LTX-002 or placebo).
Time frame: Day 1 to Day 169
Change from baseline in SPTLC1 protein concentration in cerebrospinal fluid
Change from baseline in SPTLC1 protein concentration in cerebrospinal fluid compared with placebo. Levels will be measured using a validated assay and summarized as mean change from baseline by treatment group.
Time frame: Day 1 to Day 169
Change from baseline in ceramide and other sphingolipid concentrations in cerebrospinal fluid
Change from baseline in selected ceramide and sphingolipid concentrations in cerebrospinal fluid compared with placebo. Levels will be measured using a validated assay and summarized as mean change from baseline by treatment group.
Time frame: Day 1 to Day 169
Change from baseline in plasma neurofilament light chain (NfL) concentration
Change from baseline in plasma neurofilament light chain concentration compared with placebo. Levels will be measured using a validated assay and summarized as mean change from baseline by treatment group.
Time frame: Day 1 to Day 169
Change from baseline in monocyte chemoattractant protein-1 (MCP-1) concentration in cerebrospinal fluid
Change from baseline in monocyte chemoattractant protein-1 concentration in cerebrospinal fluid compared with placebo. Levels will be measured using a validated assay and summarized as mean change from baseline by treatment group
Time frame: Day 1 to Day 169
Change from baseline in ALS Functional Rating Scale-Revised (ALSFRS-R) total score
The Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) provides a measure of how a person living with ALS is experiencing her or his disease, based on a set of 12 questions about symptoms and experiences of daily living. Each answer is given a numerical score between 0 (which indicates maximum problems or inability to perform a function) and 4 (which indicates normal functioning or no problems in this area). The total score of the ALSFRS-R thus ranges from 0 to 48, with lower scores indicating more difficulties and more severe symptoms of ALS.
Time frame: Screening through Day 169
Change from baseline in slow vital capacity (SVC)
Change from baseline in slow vital capacity compared with placebo. Results will be summarized as mean change from baseline by treatment group
Time frame: Screening to Day 169
Change from baseline in speech and bulbar function as assessed by speech analytics
Change from baseline in speech and bulbar function as assessed by speech analytics compared with placebo. Results will be summarized as change from baseline in derived speech metrics by treatment group
Time frame: Screening to Day 169
Change from baseline in muscle strength as measured by hand-held dynamometry
Change from baseline in muscle strength as measured by hand-held dynamometry compared with placebo. Results will be summarized as mean change from baseline by treatment grou
Time frame: Screening to Day 169
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Jun 2031, 62 months after the start.
Of 36 phase 1/2 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 57. This study's planned 62 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amyotrophic Lateral Sclerosis →
Leal Therapeutics, Inc